Eplerenone as a treatment for resistant hypertension in pregnancy. (March 2021)

• Record Type: Journal Article
• Authors: Gehlert, Jessica; Morton, Adam
• Is Part Of: Obstetric medicine. Volume 14:Number 1(2021)
• Page Start: 35
• Page End: 38
• Publication Date: 2021-03
• Subjects: Eplerenone -- hypertension -- mineralocorticoid receptor antagonists -- pregnancy -- obstructive sleep apnoea; Pregnancy -- Complications -- Periodicals; Obstetrics -- Periodicals; 618.2
• DOI: 10.1177/1753495X19825967
• Languages: English
• ISSNs: 1753-495X

Abstract

Mineralocorticoid receptor antagonists are highly effective in the management of resistant hypertension and primary hyperaldosteronism. Recent studies demonstrate that mineralocorticoid receptor antagonists significantly reduce blood pressure, severity of obstructive sleep apnoea and arterial stiffness in patients with resistant hypertension and moderate–severe obstructive sleep apnoea. Eplerenone is a selective mineralocorticoid receptor antagonist that does not act as an androgen receptor blocker, thus reducing the risk of fetal anti-androgenic effects. Rat and rabbit studies demonstrated that when exposed to 30 times the equivalent therapeutic human dose, 100 mg/day, there were no teratogenic or demasculinisation effects. To date, the use of eplerenone has been reported in six human pregnancies in women with Gitelman syndrome, primary hyperaldosteronism and cardiac failure, in which no teratogenic effects were seen. Described here is a case of resistant hypertension associated with obstructive sleep apnoea in pregnancy, treated with eplerenone. The potential role of using eplerenone in pregnancy as treatment for resistant hypertension is discussed. Trial registration: Not applicable.